Scolaris Content Display Scolaris Content Display

非典型溶血性尿毒综合征的治疗

Appendices

Appendix 1. Electronic search strategies

Database

Search terms

CENTRAL

  1. MeSH descriptor: [Atypical Hemolytic Uremic Syndrome] this term only

  2. "atypical hemolytic uremic syndrome":ti,ab,kw (Word variations have been searched)

  3. "atypical haemolytic uraemic syndrome":ti,ab,kw (Word variations have been searched)

  4. "atypical hemolytic uraemic syndrome".tw:ti,ab,kw (Word variations have been searched)

  5. ahus:ti,ab,kw (Word variations have been searched)

  6. {or #1‐#5}

MEDLINE

  1. Atypical Hemolytic Uremic Syndrome/

  2. atypical h?emolytic ur?emic syndrome*.tw.

  3. ahus.tw.

  4. or/1‐3

EMBASE

  1. hemolytic uremic syndrome/

  2. atypical h?emolytic ur?emic syndrome*.tw.

  3. ahus.tw.

  4. or/1‐3

Appendix 2. Risk of bias assessment tool

Potential source of bias

Assessment criteria

Random sequence generation

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence

Low risk of bias: Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).

High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.

Unclear: Insufficient information about the sequence generation process to permit judgement.

Allocation concealment

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment

Low risk of bias: Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web‐based, and pharmacy‐controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).

High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear: Randomisation stated but no information on method used is available.

Blinding of participants and personnel

Performance bias due to knowledge of the allocated interventions by participants and personnel during the study

Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Blinding of outcome assessment

Detection bias due to knowledge of the allocated interventions by outcome assessors.

Low risk of bias: No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Incomplete outcome data

Attrition bias due to amount, nature or handling of incomplete outcome data.

Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.

High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.

Unclear: Insufficient information to permit judgement

Selective reporting

Reporting bias due to selective outcome reporting

Low risk of bias: The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk of bias: Not all of the study’s pre‐specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub‐scales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear: Insufficient information to permit judgement

Other bias

Bias due to problems not covered elsewhere in the table

Low risk of bias: The study appears to be free of other sources of bias.

High risk of bias: Had a potential source of bias related to the specific study design used; stopped early due to some data‐dependent process (including a formal‐stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.

Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.

Appendix 3. Risk of bias in single arm studies assessment tool

Domain

Signalling Questions

Yes

No

Can't tell / not reported / not applicable

Quote or reason for judgement

Selection bias

1. Was the selection of participants either consecutive, or randomly selected from the population?

2a. Were the eligibility criteria clearly described?

2b. If yes, were the eligibility criteria similar to the other studies in the review that had a control group?

Lead time bias / immortal time bias

3. Was the time between starting follow‐up for outcomes (recruitment) and starting the intervention of an appropriately short duration?

4. Was it similar to other studies in the review that had a control group?

Confounding by indication

5. Are those in the study at a similar stage/severity of their disease and have similar prognostic factors to other studies in the review that had a control group?

Misclassification bias / information bias

6. Was dose (or other details) of intervention, both planned and given, clearly described?

7. Was measurement of outcome made by a reliable and valid method (e.g. objective measure)?

Bias from natural recovery / regression to the mean

8. Were outcome variables measured pre‐intervention (i.e. interrupted time series design with multiple measurements, of before‐after design)?

Bias due to adjunctive therapies

9. Is there adequate reporting of adjunctive therapies both before and during the study period?

Attrition bias

See Cochrane RoB tool

Selective reporting of outcomes

See Cochrane RoB tool

Study flow diagram.

Figuras y tablas -
Figure 1

Study flow diagram.

Summary of findings 1. Eculizumab versus placebo or alternative treatment for children and adults with atypical haemolytic uraemic syndrome (aHUS)

Eculizumab versus placebo or alternative treatment for children and adults aHUS

Patient or population: children and adults with aHUS

Settings: inpatient

Intervention: eculizumab

Comparison: placebo or alternative treatment

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No. of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Risk with placebo or alternative treatment

Risk with eculizumab treatment

Death

N/A

1/100

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

All 100 patients were alive at 26 weeks. There was 1 death in the 37 patients who were subsequently followed up over 2 years

Requirement for KRT

N/A

N/A

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

37/100 were undergoing dialysis at initiation of eculizumab therapy. Of these patients, 11 (30%) continued to require regular dialysis after 26 weeks of treatment representing a 70% reduction in dialysis requirement. At 2 years, 3/37 patients included within the secondary study remained dialysis‐dependent compared with 7 at baseline (57% reduction)

Disease remission

N/A

60/100

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

60/100 patients treated with eculizumab achieved complete TMA response after 26 weeks of treatment. Median time to complete TMA response was 56 ‐ 60 days. In a cohort of patients followed up for 2 years, 65% maintained complete TMA response at this time point

Change in eGFR

N/A

N/A

N/A

88 (3 single‐arm studies)

⊕⊝⊝⊝
very low

In patients treated with eculizumab, mean change in eGFR over 26 weeks was 33 ± 34 mL/min/1.73 m². At 2 years, eGFR had improved by ≥ 15 mL/min/1.73 m² in 37 patients (49%)

HRQoL

N/A

N/A

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

In 49 patients aged ≥ 12 years treated with eculizumab, 67% demonstrated a clinically significant improvement in EQ‐5D score. In 22 paediatric patients treated with eculizumab the mean improvement in FACIT‐F score was 19.7 (improvement of > 4.7 considered clinically meaningful)

Adverse events

N/A

100/100

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

Adverse events occurred in 100% of patients treated with eculizumab. Serious adverse events occurred in 37% of patients. The most commonly reported events included diarrhoea (23%), fever (21%), headache (19%), upper respiratory tract infection (19%), cough (17%) and urinary tract infection (10%)

Meningococcal infection

N/A

2/100

N/A

100 (4 single‐arm studies)

⊕⊝⊝⊝
very low

Meningococcal infection occurred in 2 patients (2%) treated with eculizumab

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; N/A: not applicable; KRT: Kidney replacement therapy; TMA: Thrombotic microangiopathy; eGFR: Estimated glomerular filtration rate; HRQoL: health‐related quality of life; FACIT‐F: Functional assessment of chronic illness therapy ‐ fatigue.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Figuras y tablas -
Summary of findings 1. Eculizumab versus placebo or alternative treatment for children and adults with atypical haemolytic uraemic syndrome (aHUS)
Summary of findings 2. Ravulizumab versus placebo or alternative treatment for adults with atypical haemolytic uraemic syndrome (aHUS)

Ravulizumab versus placebo or alternative treatment for adults with aHUS

Patient or population: adults with aHUS

Settings: inpatient

Intervention: ravulizumab

Comparison: placebo or alternative treatment

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No. of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Risk with placebo or alternative treatment

Risk with ravulizumab treatment

Death

N/A

4/58

N/A

58 (1 single‐arm study)

⊕⊝⊝⊝
very low

Four deaths occurred, including one in a patient ultimately excluded based on eligibility criteria but who had received one dose of ravulizumab. No deaths were considered treatment‐related by the study investigators

Requirement for KRT

N/A

N/A

N/A

56 (1 single‐arm study)

⊕⊝⊝⊝
very low

29/56 were undergoing dialysis at initiation of ravulizumab therapy. Of these patients, 12 (41%) continued to require regular dialysis after 26 weeks of treatment representing a 59% reduction in dialysis requirement

Disease remission

N/A

30/56

N/A

56 (1 single‐arm study)

⊕⊝⊝⊝
very low

30/56 patients treated with ravulizumab achieved complete TMA response after 26 weeks of treatment. Median time to complete TMA response was 86 days

Change in eGFR

N/A

N/A

N/A

56 (1 single‐arm study)

⊕⊝⊝⊝
very low

In patients treated with ravulizumab, mean change in eGFR over 26 weeks was 35 ± 35 mL/min/1.73 m²

HRQoL

N/A

N/A

N/A

44 (1 single‐arm study)

⊕⊝⊝⊝
very low

A clinically meaningful improvement in FACIT‐F score (≥ 3‐point increase) was observed in 84% of patients treated with ravulizumab

Adverse events

N/A

58/58

N/A

58 (1 single‐arm study)

⊕⊝⊝⊝
very low

Adverse events occurred in 100% of patients treated with ravulizumab. Serious adverse events occurred in 52% of patients. The most commonly reported events included headache (36%), diarrhoea (31%), vomiting (26), hypertension (22%), nausea (22%) and urinary tract infection (17%)

Meningococcal infection

N/A

0/58

N/A

58 (1 single‐arm study)

⊕⊝⊝⊝
very low

No patients treated with ravulizumab developed meningococcal infection

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio; N/A: not applicable; KRT: Kidney replacement therapy; TMA: Thrombotic microangiopathy; eGFR: Estimated glomerular filtration rate; HRQoL: Health‐related quality of life; FACIT‐F: Functional assessment of chronic illness therapy ‐ fatigue.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

Figuras y tablas -
Summary of findings 2. Ravulizumab versus placebo or alternative treatment for adults with atypical haemolytic uraemic syndrome (aHUS)